Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later?

On March 4th 2022, nivolumab received regular US Food and Drug Administration approval, based on the CheckMate 816 trial results, for use “with platinum-doublet chemotherapy for adult patients with resectable NSCLC in the neoadjuvant setting”. This is the first neoadjuvant approval of a checkpoint i...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivier, Timothée, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381437/
https://www.ncbi.nlm.nih.gov/pubmed/35953223
http://dx.doi.org/10.1016/j.tranon.2022.101505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381437/
https://www.ncbi.nlm.nih.gov/pubmed/35953223
http://dx.doi.org/10.1016/j.tranon.2022.101505

Ejemplares similares